Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T17:18:07.594Z.
Calculation as of: 2026-10-06T17:18:07.594Z.
Quote observation: 2026-10-06T17:14:18.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 8188a044afb190b383642178377b3b21d317b4c37addc3eac3f31d1e137b7514
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$125.77M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Seer, Inc. (SEER) | $121.23M | N/A | N/A | N/A | N/A |
| Cibus, Inc. (CBUS)vs › | $121.37M | N/A | N/A | N/A | N/A |
| Tenaya Therapeutics, Inc. (TNYA)vs › | $121.02M | N/A | N/A | N/A | N/A |
| enGene Holdings Inc. (ENGN)vs › | $120.58M | N/A | N/A | N/A | N/A |
| TuHURA Biosciences, Inc. (HURA)vs › | $122.27M | N/A | N/A | N/A | N/A |
| Spruce Biosciences, Inc. (SPRB)vs › | $120.19M | N/A | N/A | N/A | N/A |
| NRx Pharmaceuticals, Inc. (NRXP)vs › | $125.56M | N/A | N/A | N/A | N/A |
| Tonix Pharmaceuticals Holding Corp. (TNXP)vs › | $125.77M | N/A | N/A | N/A | N/A |
| Entera Bio Ltd. (ENTX)vs › | $125.94M | N/A | 3.95x | 3.95x | 3.95x |
| LENZ Therapeutics, Inc. (LENZ)vs › | $116.00M | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
